Company Filing History:
2 out of 26 
2 out of 2 Years Active: 2025
Title: Haijun Tian: Innovator in Therapeutic Antibodies
Introduction
Haijun Tian is a prominent inventor based in Cranbury, NJ (US), known for his significant contributions to the field of therapeutic monoclonal antibodies. With a total of 2 patents, he has made remarkable advancements in the development of innovative treatments for various medical conditions.
Latest Patents
Haijun Tian's latest patents include groundbreaking inventions in the realm of antibody technology. One of his notable patents is for an anti-CLDN18.2 antibody, which is designed to effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. This invention also encompasses nucleic acid molecules for encoding the antibody and methods for its preparation. Additionally, he has developed a pharmaceutical composition that utilizes this antibody for the prevention and treatment of tumors. Another significant patent is for an anti-FXI/FXIa antibody, which has high specificity and affinity to FXI/FXIa. This invention aims to inhibit the activity of FXI/FXIa and is intended for use in the preparation of drugs for treating coagulation disorders and thromboembolism.
Career Highlights
Throughout his career, Haijun Tian has worked with notable companies in the biopharmaceutical sector, including Sichuan Kelun Biotech Biopharmaceutical Co., Ltd. and Klus Pharma Inc. His work in these organizations has contributed to the advancement of therapeutic solutions in the medical field.
Collaborations
Haijun Tian has collaborated with esteemed colleagues such as Dengnian Liu and Sujun Deng, further enhancing the impact of his research and innovations in therapeutic antibodies.
Conclusion
Haijun Tian's contributions to the field of therapeutic antibodies exemplify his dedication to advancing medical science. His innovative patents and collaborations highlight his role as a key figure in the development of effective treatments for serious health conditions.